

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE:	ASSIGNMENT
-----------------------	------------

CONVEYING PARTY DATA

Name	Execution Date
Angiotech BioMaterials Corporation	11/02/2005

RECEIVING PARTY DATA

Name:	Angiotech Pharmaceuticals (US), Inc.
Street Address:	101 West North Bend Way
City:	North Bend
State/Country:	WASHINGTON
Postal Code:	98045

PROPERTY NUMBERS Total: 11

Property Type	Number
Patent Number:	5667839
Patent Number:	5895833
Patent Number:	5962648
Patent Number:	6111165
Application Number:	10704330
Patent Number:	6653450
Application Number:	10720831
Patent Number:	6472171
Patent Number:	6428978
Patent Number:	6413742
Patent Number:	6413737

CORRESPONDENCE DATA

Fax Number: (949)218-1767  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 9492181757

OP \$440.00 5667839

Email: richard@sci-tech.com  
Correspondent Name: Richard Aron Osman  
Address Line 1: 4070 Calle Isabella  
Address Line 4: San Clemente, CALIFORNIA 92672

ATTORNEY DOCKET NUMBER:

ANGIOTECH

NAME OF SUBMITTER:

Richard Aron Osman

Total Attachments: 4

source=AngiotechAssignment#page1.tif

source=AngiotechAssignment#page2.tif

source=AngiotechAssignment#page3.tif

source=AngiotechAssignment#page4.tif

**ASSIGNMENT OF PATENT RIGHTS  
ANGIOTECH BIOMATERIALS CORP. TO  
ANGIOTECH PHARMACEUTICALS (US), INC.**

THIS ASSIGNMENT, effective November 2, 2005, by ANGIOTECH BIOMATERIALS CORPORATION, a corporation duly organized under and pursuant to the laws of THE STATE OF DELAWARE and having a principal place of business at 2500 Faber Place, Palo Alto, CA 94303 (hereinafter referred to as the "assignor"), witnesseth:

WHEREAS, said assignor is the owner of all right, title and interest to the United States Patent Applications and Letters Patents listed at APPENDIX A, which are each recorded at the United States Patent and Trademark Office on the Reel and Frame numbers specified on APPENDIX A, and the foreign Patent Applications and Letters Patents listed at APPENDIX B, the ownership of which is of record in the respective foreign Patent Offices; and

WHEREAS, ANGIOTECH PHARMACEUTICALS (US), INC., a corporation duly organized under and pursuant to the laws of THE STATE OF DELAWARE, and having its principal place of business at 101 West North Bend Way, North Bend, Washington 98045 (hereinafter referred to as the "assignee") is desirous of acquiring the entire right, title, and interest in and to the inventions covered by the United States and foreign Patent Applications and Letters Patents specified in APPENDICES A and B, including any and all Patent Applications filed thereon in the United States or any foreign country, and any and all Letters Patent issued or granted thereon from the United States or any foreign countries;


NOW THEREFORE, for good and sufficient considerations, the receipt of which is hereby acknowledged, the assignor is hereby selling, assigning, and transferring to the assignee, its successors, legal representatives, and assigns, the entire right, title, and interest in and to the inventions covered by the United States and foreign Patent Applications and Letters Patents specified in APPENDICES A and B as well as any and all Patent Applications filed thereon in the United States of America and any foreign countries and any and all Letters Patents issued or granted thereon in the United States of America and any foreign countries, including any and all divisional applications and patents, continuation applications and patents, continuation-in-part applications and patents, reissue applications and patents, and reexamination applications and patents, and including any and all extensions of the terms of any of the Letters Patents specified in APPENDICES A and B and any and all Letters Patents issued or granted thereon in the United


**PATENT  
REEL: 017325 FRAME: 0366**

States of America and any foreign countries, and covering any and all rights under the International Convention for the Protection of Industrial Property held in any of the Patent Applications specified in APPENDICES A and B and any and all Patent Applications filed thereon in the United States of America and any foreign countries, the same to be held and enjoyed by the assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms of any of the Letters Patents issued or granted in the United States of America and all foreign countries that are covered under this assignment, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made;

AND for the same consideration, the assignor hereby covenants that at the time of execution and delivery of this assignment, the assignor is the sole and lawful owner of the entire right, title and interest in and to the inventions, the Patent Applications and Letters Patents specified in APPENDICES A and B, any and all Patent Applications filed thereon in the United States of America, and any and all Letters Patents issued or granted thereon in the United States of America and all foreign countries, and that the same are unencumbered and the assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein;

AND upon execution of this assignment, the assignor hereby requests that the Patents Offices of the United States of America and all foreign countries issue and/or grant any and all Letters Patents covered under this assignment to the assignee as the assignee of the invention, the Patent Applications and the Letters Patents specified in APPENDICES A and B, any and all Patent Applications filed thereon in the United States of America and all foreign countries, and any and all Letters Patents issued or granted thereon in the United States of America and all foreign countries, for the sole use of the assignee, its successors, legal representatives, and assigns.

  
David Parker, J.D., Ph.D.  
Vice President of Intellectual Property  
Angiotech BioMaterials Corp.

  
David Parker, J.D., Ph.D.  
Vice President of Intellectual Property  
Angiotech Pharmaceuticals (US), Inc.

APPENDIX A

Angiotech No.	Attorney Docket No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date
11.40228X1	C94-007-1	United States	Issued	08/183,648	01.18.1994	5,667,839	09.16.1997
11.40228D1	C94-007-1-D1	United States	Issued	08/485,194	06.07.1995	5,895,933	04.20.1999
11.40228D2	C94-007-1-D2	United States	Issued	08/473,465	06.07.1995	5,962,648	10.06.1999
11.40228C1	C94-007-1-D3	United States	Issued	09/232,740	01.15.1999	6,111,165	08.29.2000
11.40228C3	C94-007-1-D5	United States	Pending	10/704,330	11.06.2003		
11.40228X2	C94-018	United States	Issued	08/278,774	07.22.1994	6,653,450	11.25.2003
11.40228C4	C94-018-D2	United States	Pending	10/720,831	11.24.2003		
11.40229C1	C95-028-1	United States	Issued	09/120,561	07.22.1998	6,472,171	10.29.2002
11.40226	C98-001	United States	Issued	09/289,578	04.09.1999	6,423,978	08.06.2002
11.40226D1	C98-001-D1	United States	Issued	09/585,887	05.31.2000	6,413,742	07.02.2002
11.40227	C98-002	United States	Issued	09/608,790	06.30.2000	6,413,737	07.02.2002

APPENDIX B

Angiotech No.	Attorney Docket No.	Country	Status	Application No.	Filing Date	Patent No.	Grant Date
11.40228AU	C94-007-1/AU	Australia	Issued	60317/94	01.28.1994	706.580	09.30.1999
11.40228CA	C94-007-1/CA	Canada	Issued	2152047	01.19.1994	2152047	04.27.2004
11.40228DE	C94-007-1/EP	Germany	Issued	94906698.9	01.19.1994	0.681.431	07.13.2005
11.40228EP	C94-007-1/EP	Europe	Issued	94906698.9	01.19.1994	0.681.431	07.13.2005
11.40228FR	C94-007-1/EP	France	Issued	94906698.9	01.19.1994	0.681.431	07.13.2005
11.40228GB	C94-007-1/EP	United Kingdom	Issued	94906698.9	01.19.1994	0.681.431	07.13.2005
11.40228EP2	C94-018/EP	Europe	Issued	95108307.0	05.30.1995	0.699.752	09.24.2003
11.40228GB2	C94-018/UK	United Kingdom	Issued	95108307.0	05.30.1995	0.699.752	09.24.2003
11.40228AU	C98-001/AU	Australia	Issued	26934/99	05.04.1999	754608	11.21.2002
11.40226CA	C98-001/CA	Canada	Pending	2269148	04.23.1999		
11.40226EP	C98-001/EU	Europe	Pending	99303470.1	05.04.1999		
11.40226JP	C98-001/JP	Japan	Pending	11-126492	05.06.1999		
11.40227JP	C99-002/JP	Japan	Pending	2001-509755	07.09.1999		

RECORDED: 03/19/2006

PATENT  
REEL: 017325 FRAME: 0369